On a deal spree, Take­da grabs Japan­ese cabo rights in $145M pact with Ex­elix­is

A deal-hun­gry Take­da has stepped up with a $145 mil­lion pact to part­ner with Ex­elix­is on cabozan­ti­nib.

Ex­elix­is $EX­EL grabbed a $50 mil­lion up­front in the deal, and stands to earn an­oth­er $95 mil­lion in mile­stones, as Take­da takes a lead role in de­vel­op­ing cabo for the Japan­ese mar­ket.

“We in­tend to pur­sue reg­u­la­to­ry ap­proval for (re­nal cell car­ci­no­ma) in­di­ca­tions as soon as we’re able, and look for­ward to com­menc­ing the lo­cal clin­i­cal tri­al pro­gram to fur­ther strength­en the clin­i­cal pro­file of cabozan­ti­nib,” said Tsu­doi Miyoshi, head of Japan On­col­o­gy Busi­ness Unit of Take­da.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER